{
    "id": 1185,
    "fullName": "AKT1 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "AKT1 mutant indicates an unspecified mutation in the AKT1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 207,
        "geneSymbol": "AKT1",
        "terms": [
            "AKT1",
            "AKT",
            "CWS6",
            "PKB",
            "PKB-ALPHA",
            "PRKBA",
            "RAC",
            "RAC-ALPHA"
        ]
    },
    "variant": "mutant",
    "createDate": "07/28/2014",
    "updateDate": "08/22/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16717,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (9.3 vs 3.7 months, HR=0.30, p=0.01) compared to placebo in patients with metastatic triple-negative breast cancer harboring PIK3CA, AKT1, and/or PTEN mutations, but not in patients with wile-type PIK3CA, AKT1, and PTEN (5.3 vs 4.4 months, HR=1.13, p=0.61) (PMID: 30715161; NCT02423603).",
            "molecularProfile": {
                "id": 1209,
                "profileName": "AKT1 mutant"
            },
            "therapy": {
                "id": 2192,
                "therapyName": "Capivasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14752,
                    "pubMedId": 30715161,
                    "title": "Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715161"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5205,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)).",
            "molecularProfile": {
                "id": 1209,
                "profileName": "AKT1 mutant"
            },
            "therapy": {
                "id": 750,
                "therapyName": "GDC-0980",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4913,
                    "pubMedId": null,
                    "title": "Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.",
                    "url": "http://meetinglibrary.asco.org/content/132500-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10325,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, AKT1 mutations were more frequent in muscle-invasive urothelial bladder cancer patients that did not respond to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy than those who did respond (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).",
            "molecularProfile": {
                "id": 1209,
                "profileName": "AKT1 mutant"
            },
            "therapy": {
                "id": 5462,
                "therapyName": "Cisplatin + Gemcitabine + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 6477,
                "name": "invasive bladder transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8305,
                    "pubMedId": null,
                    "title": "Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase II study.",
                    "url": "http://meetinglibrary.asco.org/content/179076-197"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6401,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study of a Phase II trial, Torisel (temsirolimus) treatment resulted in an increased progression-free survival (HR 0.16) and response rate (response difference 0.83) in advanced endometrial cancer patients harboring AKT1 mutations (PMID: 27016228).",
            "molecularProfile": {
                "id": 1209,
                "profileName": "AKT1 mutant"
            },
            "therapy": {
                "id": 936,
                "therapyName": "Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5557,
                    "pubMedId": 27016228,
                    "title": "Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27016228"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11169,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).",
            "molecularProfile": {
                "id": 1209,
                "profileName": "AKT1 mutant"
            },
            "therapy": {
                "id": 1588,
                "therapyName": "Ipatasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9130,
                    "pubMedId": null,
                    "title": "LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).",
                    "url": "http://abstracts.asco.org/199/AbstView_199_183382.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1209,
            "profileName": "AKT1 mutant",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}